Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lumos Pharma Inc (NQ: LUMO ) 1.540 +0.040 (+2.67%) Streaming Delayed Price Updated: 3:57 PM EDT, Jul 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 76,832 Open 1.520 Bid (Size) 1.380 (11) Ask (Size) 1.660 (1) Prev. Close 1.500 Today's Range 1.390 - 1.690 52wk Range 1.370 - 4.550 Shares Outstanding 8,357,391 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024 June 04, 2024 From Lumos Pharma, Inc. Via GlobeNewswire Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024 May 20, 2024 From Lumos Pharma, Inc. Via GlobeNewswire Performance YTD -52.17% -52.17% 1 Month -33.04% -33.04% 3 Month -38.89% -38.89% 6 Month -44.20% -44.20% 1 Year -51.72% -51.72% More News Read More LUMO Stock Earnings: Lumos Pharma Misses EPS, Misses Revenue for Q1 2024 May 14, 2024 Via InvestorPlace Lumos Pharma: Q4 Earnings Insights March 07, 2024 Via Benzinga Earnings Preview: Lumos Pharma March 06, 2024 Via Benzinga Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results May 14, 2024 From Lumos Pharma, Inc. Via GlobeNewswire Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024 May 09, 2024 From Lumos Pharma, Inc. Via GlobeNewswire Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings April 18, 2024 From Lumos Pharma, Inc. Via GlobeNewswire BioMedNewsBreaks – Lumos Pharma Inc. (NASDAQ: LUMO) Receives Patent Notice for Improved Formulation of Lead Therapeutic Candidate March 25, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042 March 20, 2024 From Lumos Pharma, Inc. Via GlobeNewswire LUMO Stock Earnings: Lumos Pharma Misses EPS for Q4 2023 March 07, 2024 Via InvestorPlace Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update March 07, 2024 From Lumos Pharma, Inc. Via GlobeNewswire Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024 February 26, 2024 From Lumos Pharma, Inc. Via GlobeNewswire Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference February 05, 2024 From Lumos Pharma, Inc. Via GlobeNewswire Earnings Scheduled For March 7, 2024 March 07, 2024 Via Benzinga Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer January 04, 2024 From Lumos Pharma, Inc. Via GlobeNewswire Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency November 21, 2023 From Lumos Pharma, Inc. Via GlobeNewswire Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November November 20, 2023 From Lumos Pharma, Inc. Via GlobeNewswire Why Toast Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session November 08, 2023 Via Benzinga Why Is Biomarin & BridgeBio Pharma Rival Lumos Pharma Stock Trading Higher Today? November 08, 2023 Via Benzinga Roblox, Under Armour, GoPro, Nuvei And Other Big Stocks Moving Higher On Wednesday November 08, 2023 Via Benzinga Topics Stocks Exposures US Equities 12 Health Care Stocks Moving In Wednesday's Pre-Market Session November 08, 2023 Via Benzinga Why American Public Education Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket November 08, 2023 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday November 08, 2023 Via InvestorPlace Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates November 07, 2023 From Lumos Pharma, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
